CNBCLean R·
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Read at CNBC →
Business · 1 sources covering this
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/1fc3deb39b3990ce9e088ea85e0bdf09d5af7990" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production"></iframe>
